The comparative clinical pharmacology of vincristine and vindesine: Does vindesine offer any advantage in clinical use?

被引：22

作者：

Joel, S

机构：

[1] Medical Oncology Department, St Bartholomew's Hospital, London

来源：

CANCER TREATMENT REVIEWS | 1995年 / 21卷 / 06期

关键词：

D O I：

10.1016/0305-7372(95)90015-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：513 / 525

页数：13

共 76 条

[1]

ANDERSON J, 1981, CANCER TREAT REP, V65, P1015

[2]

BACCARANI M, 1982, CANCER CHEMOTH PHARM, V8, P255

[3] STRUCTURE-ACTIVITY-RELATIONSHIPS OF DIMERIC CATHARANTHUS ALKALOIDS .1. DEACETYLVINBLASTINE AMIDE (VINDESINE) SULFATE [J].

BARNETT, CJ ;

CULLINAN, GJ ;

GERZON, K ;

HOYING, RC ;

JONES, WE ;

NEWLON, WM ;

POORE, GA ;

ROBISON, RL ;

SWEENEY, MJ ;

TODD, GC ;

DYKE, RW ;

NELSON, RL .

JOURNAL OF MEDICINAL CHEMISTRY, 1978, 21 (01) :88-96

[4]

BARNETT CJ, 1979, CANCER RES, V39, P1604

[5] PHASE-II TRIAL WITH VINDESINE FOR REGRESSION INDUCTION IN PATIENTS WITH LEUKEMIAS AND HEMATOSARCOMAS [J].

BAYSSAS, M ;

GOUVEIA, J ;

RIBAUD, P ;

MUSSET, M ;

VASSAL, FD ;

PICO, JL ;

LUCA, LD ;

MISSET, JL ;

MACHOVER, D ;

BELPOMME, D ;

SCHWARZENBERG, L ;

JASMIN, C ;

HAYAT, M ;

MATHE, G .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1979, 2 (04) :247-255

[6]

BENDER RA, 1977, CLIN PHARMACOL THER, V22, P430

[7]

BUCHANAN GR, 1988, BLOOD, V72, P1286

[8]

BUDMAN DR, 1992, SEMIN ONCOL, V19, P639

[9]

CANELLOS GP, 1990, SEMIN ONCOL, V17, P2

[10]

Cavalli F, 1991, Baillieres Clin Haematol, V4, P157, DOI 10.1016/S0950-3536(05)80289-6

← 1 2 3 4 5 6 7 8 →